Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556478 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
A Phase 2 study, sponsored by Plethora Solutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT00556478: Completed Phase 2 study, sponsored by Plethora Solutions.
NCT00556478 is a Phase 2 study that has completed, run by Plethora Solutions. The registered enrollment target is 256 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00556478, a Phase 2 study, has completed, sponsored by Plethora Solutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of the investigational drug, PSD502 in subjects with premature ejaculation (PE) The study drug, PSD02, is a metered dose (measured dose), topical (applied to the skin surface) anesthetic (numbing) spray containing a mixture of lidocaine and prilocaine. The study drug will be applied in a spray to the penis prior to intercourse in order to decrease sensitivity in an attempt to delay ejaculation.
Interventions
- DRUG Placebo
- DRUG PSD502, contains a mixture of lidocaine and prilocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556478
The ClinicalTrials.gov registry entry for NCT00556478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Plethora Solutions, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00556478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00556478 about?
NCT00556478 is a clinical study titled "Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation". The purpose of this study is to evaluate the effectiveness, safety and tolerability of the investigational drug, PSD502 in subjects with premature ejaculation (PE) The study drug, PSD02, is a metered dose (measured dose), topical (applied to the skin surface) anesthetic (numbing) spray containing a ...
What is the current status of trial NCT00556478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2007-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00556478?
The interventions under investigation include: Placebo (DRUG), PSD502, contains a mixture of lidocaine and prilocaine (DRUG).
Who is sponsoring clinical trial NCT00556478?
This trial is sponsored by Plethora Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.